This is a double-blind, randomized, multicenter international Phase 3 study of CAEL-101 combined with the SoC treatment for plasma cell dyscrasia (PCD) versus placebo combined with standard of care PC
Sponsors
Caelum Medical Monitor, Caelum Medical Monitor
Conditions
AL Amyloidosis
Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of CAEL-101 in Plasma Cell Dyscrasia Treatment Naive Patients with Mayo Stage IIIb AL Amyloidosis
Active, not recruitingJPRN-jRCT2031200299
Start: 2021-01-15Target: 3Updated: 2026-06-29
A Phase 3 Study to Evaluate the Efficacy and Safety of CAEL-101 in Plasma Cell Dyscrasia Treatment Naive Patients with Mayo Stage IIIa AL Amyloidosis
Active, not recruitingJPRN-jRCT2031200300
Start: 2021-01-15Target: 9Updated: 2026-06-29